Inadequate investigations were a major focus of recent drug GMP inspections by the US Food and Drug Administration and EU national authorities that resulted in serious findings, with consequences so far of two FDA warning letters and two EU good manufacturing practices noncompliance notices.
Other key focus areas: process validation, data integrity and contamination.





